



US006210976B1

(12) **United States Patent**  
**Sabbadini**

(10) **Patent No.:** **US 6,210,976 B1**  
(45) **Date of Patent:** **Apr. 3, 2001**

(54) **METHODS FOR EARLY DETECTION OF HEART DISEASE**

(75) Inventor: **Roger A. Sabbadini**, Lakeside, CA (US)

(73) Assignee: **Medlyte Diagnostics, Inc.**, Lakeside, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/084,069**

(22) Filed: **May 22, 1998**

**Related U.S. Application Data**

(60) Provisional application No. 60/049,274, filed on Jun. 10, 1997.

(51) **Int. Cl.<sup>7</sup>** ..... **G01N 33/543**

(52) **U.S. Cl.** ..... **436/518**; 435/7.1; 435/7.92; 435/7.93; 435/7.94; 436/71; 436/811; 436/815

(58) **Field of Search** ..... 435/7.1, 7.92, 435/7.93, 7.94; 436/518, 71, 811, 815

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,376,110	3/1983	David et al.	436/513
5,223,409	6/1993	Ladner et al.	435/69.7
5,290,678	3/1994	Jackowski	435/7.4
5,403,484	4/1995	Ladner et al.	435/235.1
5,604,105	2/1997	Jackowski	435/7.4
5,710,008	1/1998	Jackowski	435/7.4

**OTHER PUBLICATIONS**

Andrieu-Abadie et al., "L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation," *FASEB* 13:1501-1510 (1999).

Bartels et al., "Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris," *Am J Cardiol* 74(2):125-30 (1994).

Bielawska et al., "Ceramide Is Involved in Triggering of Cardiomyocyte Apoptosis Induced by Ischemia and Reperfusion," *American Journal of Pathology* 151(5):1257 (1997).

Cordis et al., "HPTLC analysis of sphingomyelin, ceramide and sphingosine in ischemic/reperfused rat heart," *Journal of Pharmaceutical and Biomedical Analysis* 16:1189-1193 (1998).

Corr et al., "Amphipathic Metabolites and Membrane Dysfunction in Ischemic Myocardium," *Circulation Research* 55(2):135-154 (1984).

Daleau, "Sysophosphatidylcholine, a Metabolite which Accumulates Early in Myocardium During Ischemia, Reduces Gap Junctional Coupling in Cardiac Cells," *J Mol Cell Cardiol* 31:1391-1401 (1999).

DaTorre et al., "Amphipathic Lipid Metabolites and their Relation to Arrhythmogenesis in the Ischemic Heart," *J Mol Cell Cardiol* 23:11-22 (1991).

Derwent Publications Ltd., London, GB; AN 94-090594, XP002079555 (no date).

Hashizume et al., "A new approach to the development of anti-ischemic drugs. Substances that counteract the deleterious effect of lysophosphatidylcholine on the heart," *Jpn Heart J* 38(1):11-25 (1997).

Kubota et al., "Accumulation of Ceramide in Ischemic Human Brain of an Acute Case of Cerebral Occlusion," *J. Exp. Med.* 59(2):59-64 (1999).

(List continued on next page.)

*Primary Examiner*—Christopher L. Chin

(57) **ABSTRACT**

The invention relates to methods, compositions, kits, and devices for detecting cardiac ischemia, hypoxia, or other causes of heart failure in a mammal by obtaining a test sample from a mammal, measuring a level of a non-polypeptidic cardiac marker in the test sample, and determining if the level of the cardiac marker measured in said test sample correlates with cardiac ischemia or hypoxia or another form of heart failure.

**40 Claims, 1 Drawing Sheet**

